42 | 0 | 2 |
下载次数 | 被引频次 | 阅读次数 |
目的 探讨脑动脉高密度征的临床特点,评价脑动脉高密度征行静脉溶栓的安全性及有效性。方法 回顾性分析15例入院前行头部CT发现脑动脉高密度征后且有神经缺失症状患者行静脉溶栓病例的临床资料及随访结果。其中采用尿激酶5例,阿普替酶(rt-PA)10例。结果 溶栓后复查CT、CTA及MRA造影随访7例,DSA造影随访4例,随访时间318个月,平均10.4个月。所有患者临床症状均得到不同程度的改善,并未再次发生梗死或出血。结论 脑动脉高密度征行静脉溶栓可改善临床症状,且安全性好。
Abstract:Objective To explore the clinical characteristics of hyperdense cerebral artery sign,evaluatethe safety and efficacy of hyperdense cerebral artery sign treated with intravenous thrombolysis. Methods Retrospectively analyzed the clinical data and follow-up results of 15 cases that were found out havinghyperdense cerebral artery sign with CT and having neurological deficit symptoms,and the 15 caseswere treated with intravenous thrombolysis. Among the 15 cases,5 were treated with urokinase and 10 were treated with alteplase(rt-PA). Results After thrombolysis,re-examined with CT,CTA and MRAangiography followed up in 7 cases,DSA angiography followed up in 4 cases,follow-up time was 3 to18 months,average 10.4 months. The clinical symptoms of all the patients are different degree im-proved,there were not infarction and hemorrhage happened again. Conclusion The hyperdense cerebralartery sign treated with intravenous thrombolytic therapy can improve the clinical symptoms,and thesafety is good.
[1]孙威,丁则昱,张静波,等.急性脑梗死患者多模式CT指导下的静脉溶栓治疗[J].中华神经科杂志,2010,43(4):256-258.
[2]曲东锋.伴有动脉高密度征的缺血性卒中患者可从静脉溶栓治疗中获益[J].国际脑血管病杂志,2006,6(14):436-437.
[3]重组组织型纤溶酶原激活剂治疗缺血性卒中共识专家组.重组组织型纤溶酶原激活剂静脉溶栓治疗缺血性卒中中国专家共识(2012版)[J].中华内科杂志,2012,51(12):1006-1008.
[4]国家“九五”攻关课题协作组.急性脑梗塞6小时以内的静脉溶栓治疗[J].中华神经科杂志,2002,35(4):210-212.
[5]HILL M D,WEIR N U.Is the ABCD score truly useful[J].Stroke,2006,37(7):636-637.
基本信息:
DOI:10.16389/j.cnki.cn42-1737/n.2015.01.015
中图分类号:R743.3
引用信息:
[1]欧阳方.脑动脉高密度征行静脉溶栓的临床疗效分析[J].江汉大学学报(自然科学版),2015,43(01):88-90.DOI:10.16389/j.cnki.cn42-1737/n.2015.01.015.
基金信息: